<DOC>
	<DOCNO>NCT02926937</DOCNO>
	<brief_summary>Primary Objective : To demonstrate superiority sotagliflozin versus placebo hemoglobin A1c ( HbA1c ) reduction patient type 2 diabetes ( T2D ) inadequate glycemic control diet exercise . Secondary Objectives : - To compare sotagliflozin versus placebo base : - Change baseline 2-hour postprandial glucose ( PPG ) follow mixed meal ; - Change baseline fast plasma glucose ( FPG ) ; - Change baseline body weight ; - Change baseline systolic blood pressure ( SBP ) patient baseline SBP ≥130 mmHg ; - Change baseline SBP patient ; - Proportion patient HbA1c &lt; 6.5 % , &lt; 7.0 % . - To evaluate safety sotagliflozin versus placebo .</brief_summary>
	<brief_title>Efficacy Safety Sotagliflozin Versus Placebo Drug-naïve Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>Up 34 week , include Screening Period consist Screening Phase 2 week 2-week single-blind placebo Run-in Phase , 26-week double-blind Treatment Period , 4-week post-treatment Follow-up visit collect safety information .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<criteria>Inclusion criterion : Patients ( male female ) T2D , treat diet exercise 12 week prior screen . Signed write informed consent . Exclusion criterion : Age &lt; 18 year Screening Visit . Type 1 diabetes mellitus . Hemoglobin A1c &lt; 7 % &gt; 10 % via central laboratory test Screening . Fasting plasma glucose ( FPG ) &gt; 15 mmol/L ( 270 mg/dL ) measure central laboratory screening ( Visit 1 ) confirm repeat test ( &gt; 15 mmol/L [ 270 mg/dL ] ) randomization . Women childbearing potential effective contraceptive method . Treated antidiabetic pharmacological agent within 12 week prior Screening Visit . Previous insulin use &gt; 1 month ( time , aside treatment gestational diabetes ) . History gastric surgical procedure include gastric banding within 3 year Screening Visit . History diabetic ketoacidosis nonketotic hyperosmolar coma within 12 week prior Screening Visit . Blood pressure &gt; 180 mmHg ( systolic ) &gt; 95 mmHg ( diastolic ) . History hypertensive emergency . Patients severe anemia , severe cardiovascular ( include congestive heart failure New York Heart Association ( NYHA ) III/IV ) , respiratory , hepatic , neurological , psychiatric , active malignant tumor major systemic disease patient short life expectancy make implementation protocol interpretation study result difficult . Aspartate aminotransferase and/or alanine aminotransferase : &gt; 3 time upper limit normal laboratory range . Total bilirubin : &gt; 1.5 time upper limit normal laboratory range ( except case Gilbert 's syndrome ) . Use systemic glucocorticoid ( exclude topical ophthalmic application inhale form ) 10 consecutive day within 90 day prior Screening Visit . Patient take investigational drug prohibit therapy study within 12 week 5 halflives screen randomization , whichever longer . Pregnant ( demonstrate serum pregnancy test Screening ) breastfeed woman . Severe renal disease define estimate glomerular filtration rate ( eGFR ) &lt; 30 mL/min/1.73m² screen 4 variable Modification Diet Renal Disease ( MDRD ) equation . Patient unwilling perform selfmonitoring blood glucose ( SMBG ) complete patient diary require per protocol . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>